Trial Profile
Clinical Phase Ib/II Trial of L-NMMA Plus Taxane Chemotherapy in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Aspirin (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Pegfilgrastim (Primary) ; Tilarginine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research
- 28 May 2021 Status changed from recruiting to completed.
- 21 May 2021 Results (n=35) presented at the 112th Annual Meeting of the American Association for Cancer Research